Journal of Stem Cell Research and Medicine最新文献

{"title":"Use of autologous bone marrow rich in stem cells as an osteoinducer in maxillary sinus elevation","authors":"Ibañez Juan Carlos, Juaneda Maria Agustina, Ibanez María Constanza, Ibañez Santiago Luis","doi":"10.15761/jscrm.1000140","DOIUrl":"https://doi.org/10.15761/jscrm.1000140","url":null,"abstract":"Aim: To study the results that can be obtained when performing sinus lift technique by lateral opening with piezo surgery using as graft material a mixture of autologous bone marrow without any treatment and Bio-Oss (60:40) measuring the amount of bone tissue formed in the maxillary sinuses, the percentage of final vital bone obtained in the grafts and the success rate of the implants placed in those sinuses. Materials and methods: 23 maxillary sinus lifting were performed in 13 patients (10 bilateral, 3 unilateral) using a mixture of bone marrow taken from distal femur with a xenograft (Bio-Oss) Lateral window sinus elevation technique using piezo surgery was used in all cases. 49 implants were placed and loaded. Graft volume, height and density were measure. Besides percentages of new bone, biomaterial remnant and connective tissue were also measure. Results : Mean volume obtained was 1668 mm3, mean height was 10.9 mm and bone density was 648 HU. Percentage of new bone, biomaterial remnant and connective obtained were 37.08, 16.77 and 45.22 respectively. Finally, the percentage of success of the implants inserted in these grafted sinuses was 96% Conclusions: The use of a mixture of Bio-Oss with bone marrow obtained from the distal femur seems to be an efficient combination to obtain an adequate percentage of vital bone when sinus lifting is performed. Besides good results can be achieved when implants with microtextured surface are used in this type of sinus graft.","PeriodicalId":318869,"journal":{"name":"Journal of Stem Cell Research and Medicine","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125117437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late effects after allogeneic hematopoietic cell transplantation with busulphan conditioning in 33 childhood leukemia survivors (1987-2013)","authors":"F. Freycon, L. Casagranda, B. Trombert-Paviot, C. Berger","doi":"10.15761/jscrm.1000139","DOIUrl":"https://doi.org/10.15761/jscrm.1000139","url":null,"abstract":"Late effects (LE) after busulphan (BU) conditioning Hematopoietic Cell Transplantation (HCT) in childhood leukemia survivors are rarely studied. LE were retrospectively collected for 33 childhood leukemia survivors (median age 21y at follow-up) treated with BU myeloablative conditioning allogeneic HCT. Median delay after HCT was 14.0y and median age at evaluation was 21.0y (17.0-33.5). Patients had a chronic Graft versus Host Disease (cGvHD) (n=3). The mean number of severe late effects was 1.1 per patient: decreased height at adulthood (n=4); Growth Hormone deficit (n=1); risk of impaired fertility (n=14/18 females; n=7/15 males; 2 women had a child); iron overload (n=3); mellitus diabetes (n=1); pulmonary LE (n=2); psychiatric disorders (n=3); sclerodermic cGvHD (n=1); severe academic difficulties (n=3). On the contrary, we found no cardiac, renal or CNS LE, and no secondary cancer. Among the other non-severe LE, there was: alopecia (n=3); treated hypogonadism (n=13 all females); low weight (n=10); minor overweight (n=13); hepatic focal nodular hyperplasia (n=9); dental hypoplasia (n=6); osteopenia (n=4); hypertriglyceridemia (n=4); moderate cataract (n=1). Conclusion: The mean number of severe late effects was 1.1 (±1.0) per patient, significantly less than in our other cohort of 71 children grafted after TBI conditioning published in 2019 (2.3 ±1.5; p<0.0001). *Correspondence to: Léonie Casagranda, Department of Pediatric Hematology and Oncology Unit, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 02, France, Tel: +33 477 127 937, E-mail: leonie.casagranda@chu-stetienne.fr","PeriodicalId":318869,"journal":{"name":"Journal of Stem Cell Research and Medicine","volume":"569 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114671291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How can you describe personal medicine?","authors":"E. Gulik","doi":"10.15761/jscrm.1000135","DOIUrl":"https://doi.org/10.15761/jscrm.1000135","url":null,"abstract":"The term personal medicine may also be used, indicating precision medicine, corresponding to the function of medical approach to the patient. In cases of blood transfusion or organ transplantation precision medicine will be taking into account individual variability in genes. Environment and lifestyle are other factors in determination of a specialised treatment and could be considered as precision medicine. In that context prevention and therapy are both part of precision medicine.","PeriodicalId":318869,"journal":{"name":"Journal of Stem Cell Research and Medicine","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129116968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-clinical evaluation of the treatment with MSCs of fistular pathology in inflammatory bowel diseases","authors":"L. Mariñas-Pardo, L. Núñez-Naveira, M. Hermida-Prieto","doi":"10.15761/jscrm.1000136","DOIUrl":"https://doi.org/10.15761/jscrm.1000136","url":null,"abstract":"Perianal disease includes the presence of fistulas, abscesses, fissures and stenoses that place a burden on the patient due to perianal losses, pain and a decrease in quality of life. It is a disease in which the body produces an immune reaction against itself. The traditional treatment of this pathology includes the use of antibiotics and immunomodulatory drugs or surgery. However, surgery may not always be performed due to the inherent risk of the procedure or the incontinence sequelae it may cause.","PeriodicalId":318869,"journal":{"name":"Journal of Stem Cell Research and Medicine","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127938178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanotoxicity at the interface of stem cell niche- A researcher’s responsibility","authors":"D. Nath, Anugrah Ray, Baishakhi Bairagi","doi":"10.15761/jscrm.1000134","DOIUrl":"https://doi.org/10.15761/jscrm.1000134","url":null,"abstract":"Nanotechnology is going to occupy the twenty first century as tiny ‘demons’ as J C Maxwell imagined. The credit goes to the most famous and brilliant Caltech physicist Richard Phillips Feynmann who delivered an after-dinner lecture on December 29, 1959 at the annual meeting of American Physical society called “There’s plenty of room at the bottom”. He boldly declared that “the principle of physics, as far as I can see, do not speak against the possibility of manoeuvring things atom by atom” in fact, he saw the atomic manipulation was inevitable and “cannot be avoided” [1].","PeriodicalId":318869,"journal":{"name":"Journal of Stem Cell Research and Medicine","volume":"134 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116577073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of B lymphocytes in tumour immune response","authors":"N. Goret, C. Goret, U. Topal, Omer Faruk Ozkan","doi":"10.15761/jscrm.1000133","DOIUrl":"https://doi.org/10.15761/jscrm.1000133","url":null,"abstract":"B cells have often been ignored in tumor immunology for years, with the idea that humoral and cytolytic responses work against each other; instead CD8+ T lymphocytes were focused on for tumor immunology, because of their ability to directly kill tumor cells. In studies conducted to date, the role of B lymphocytes in tumor immunity has been largely unclear, and the results from the research groups are controversial; nowadays, many antitumor responses of B cells have been determined and molecular mechanisms have been tried to be defined. B cells are phenotypically and functionally heterogeneous and have been reported to play an important role in the antitumor response. An understanding of the molecular mechanisms of B cells in tumor immunology and the characterization of the functions of B cells will help to develop new clinical strategies for cancer immunotherapy, as well as be a guide to predict the clinical outcomes of patients with carcinoma and to identify more effective treatments. *Correspondence to: Ceren Canbey Goret, Department of Surgical Pathology, Sancaktepe Research and Education Hospital, Health Sciences University, Floor 0, Istanbul, Turkey, Tel: +905079500212; E-mail: drcerencanbey@hotmail.com","PeriodicalId":318869,"journal":{"name":"Journal of Stem Cell Research and Medicine","volume":"136 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116038210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiogenesis in Bone Tissue Engineering","authors":"M. Bienert","doi":"10.15761/JSCRM.1000129","DOIUrl":"https://doi.org/10.15761/JSCRM.1000129","url":null,"abstract":"Received: Septenber 25, 2018; Accepted: October 18, 2018; Published: October 24, 2018 Blood vessel formation is described by two distinct mechanisms called vasculogenesis and angiogenesis [1]. During vasculogenesis, the first primitive vascular plexus and the heart form inside the developing embryo and new blood vessels arise out of mesodermal-derived hemangioblasts. Angiogenesis is defined as the formation of new blood vessels out of the existing vasculature in order to support vascular network expansion and remodelling. Network expansion is based on endothelial cell proliferation, migration and tube formation [2]. Since the passive transport by diffusion of oxygen and nutrients is limited by tissue thickness, a blood vessel is necessary every 100-200 μm to support active nutrient supply and waste product removal [3]. Tissue supply with nutrients through blood vessels is not only important for organ homeostasis, it is also necessary for tissue regeneration and wound healing, which are important elements addressed in bone tissue engineering (BTE). Bone is an adult tissue that has the ability to heal itself when a specific size is not exceeded (so called critical size defect). However, the healing can be disturbed, making bone reconstruction after trauma impossible. Reconstructive surgical therapies currently use autologous, allogeneic and synthetic materials to fill the bone defects [4]. Autologous bone replacement is the gold standard in term of osteoinduction and osteoconduction. A disadvantage is that it is only available in limited amounts and in addition to the surgical intervention for defect reconstruction an additional surgery is required to obtain the autologous bone from the patient [5]. In comparison to autologous grafts, allografts are available in much higher quantities and shapes. However, they have a lower osteoinductivity compared to autologous grafts, which can lead to worse healing compared to autologous grafts. Thus, synthetic grafts like for example ceramics, metals or polymers are considered for BTE [5–7]. In contrast to autologous grafts, synthetic grafts do not provide the cellular elements necessary for osteogenesis and therefore exhibit lower osteoinductivity than autologous bone substitutes [8]. Since decades, insufficient vascularization hinders the translation of engineered bone constructs into the clinics. In addition, support of a bone environment rich in vascular networks is important for the tissue integration and its functionality after bone graft implantation [9] underlining the important role of angiogenesis and endothelial cells in BTE. Approaches discussed in the literature to increase vascularization include seeding cells on bone grafts and the control and guidance of vascular structure growth [10].","PeriodicalId":318869,"journal":{"name":"Journal of Stem Cell Research and Medicine","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114503138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How the artificial intelligence tool iSNO-PseAAC is working in predicting the cysteine S-nitrosylation sites in proteins","authors":"K. Chou","doi":"10.15761/jscrm.1000137","DOIUrl":"https://doi.org/10.15761/jscrm.1000137","url":null,"abstract":"Step 2. Either type or copy/paste the query protein sequences into the input box shown at the center of Figure 1. The input sequence should be in the FASTA format. A sequence in FASTA format consists of a single initial line beginning with a greater-than symbol (“>”) in the first column, followed by lines of sequence data. The words right after the “>” symbol in the single initial line are optional and only used for the purpose of identification and description. All lines should be no longer than 120 characters and usually do not exceed 80 characters. The sequence ends if another line starting with a “>” appears; this indicates the start of another sequence. Example sequences in FASTA format can be seen by clicking on the Example button right above the input box.","PeriodicalId":318869,"journal":{"name":"Journal of Stem Cell Research and Medicine","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122518330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analytical lights and shadows in metabolomics research on obstructive sleep apnea","authors":"Castillo-Peinado Ls, B. Jurado-Gámez, L. Castro","doi":"10.15761/jscrm.1000142","DOIUrl":"https://doi.org/10.15761/jscrm.1000142","url":null,"abstract":"index: Homeostatic model assessment for insulin resistance, LC–QTOF/MS: Liquid chromatography–quadrupole time of flight–mass spectrometry, LC–TOF/MS: Liquid chromatography– mass spectrometry, LC–MS/MS: Liquid chromatography coupled with tandem mass spectrometry, mRNA: Messenger RNA, NMR: Nuclear magnetic resonance, QCs: Quality controls, OA CEAS: Off axis cavity enhanced absorption spectroscopy, OSA: Obstructive sleep apnea (obstructive sleep apnoea), PLS–DA: partial least squares discriminant analysis, PSG: Polysomnography, ROC: Receiver–operator characteristic, SESI–MS: Secondary–electrospray–ionization–mass spectrometry, SIL–ISs: Stable isotopic labeled internal standards, TD–GC–MS: Thermal desorption gas chromatography mass spectrometry, TRP: Tryptophan, VOCs: Volatile organic compounds Abstract A critical opinion about how clinical researchers face to the metabolomics–obstructive sleep apnea (OSA) binomial is here presented from the point of view of analytical chemists. Thus, positive and negative (lights and shadows) aspects related to the types of samples used for the target studies, the pros and cons of the devices used for sampling and present storage conditions, and actions for their improvement are expressed. Sample preparation and its multiple facets that required to be clarified are discussed, as well as those related to analysis. A key aspect as data treatment has been discussed in the light of the cohorts handled to obtain the information to be subjected to appropriate/inappropriate treatment, and support on suitable examples has been provided. The search for OSA biomarkers, one of the areas to which key investigations are devoted at present, is critically discussed by showing the weak points and proposing new ways for improvement. A final section is devoted to aspects that may help to improve metabolomics–OSA research, a field asking for more attention.","PeriodicalId":318869,"journal":{"name":"Journal of Stem Cell Research and Medicine","volume":"782 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122996791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in patients with dry age-related macular degeneration (dry AMD) treated with intravitreal bone marrow-derived stem cells (AMDCELL-clinical trial)","authors":"R. Siqueira, C. C. Cotrim, Luiza Toscano, M. Orellana, A. Messias, R. Jorge","doi":"10.15761/JSCRM.1000130","DOIUrl":"https://doi.org/10.15761/JSCRM.1000130","url":null,"abstract":"Background: Dry age-related macular degeneration (dry AMD) is a severe neurodegenerative disease of the retina that can lead to blindness. We assessed the visionrelated quality of life in patients with dry AMD treated with intravitreal bone marrow-derived stem cells. Methods: The study included 10 patients with dry AMD treated with intravitreal bone marrow-derived stem cells. The vision-related quality of life was evaluated using the National Eye Institute Visual Function Questionnaire-25. Patients answered a questionnaire before treatment and 3 and 12 months after treatment. Results: All patients completed the survey as scheduled. There was a statistically significant improvement (p < 0.05) in the quality of life of patients 6 months after treatment, especially in mental health (p = 0.003), colour vision (p = 0.005), general vision (p = 0.05), and dependence (p = 0.067). There was a decline in general health (p = 0.77). There were improvements in the answers to other questions, but the results were not statistically significant. Conclusion: Cell therapy with intravitreal bone marrow-derived stem cells improved the quality of life of patients with dry AMD. A larger number of cases will be necessary to more fully evaluate the effects of this therapy on the quality of life of these patients. *Correspondence to: Rubens Camargo Siqueira, Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirao Preto School of Medicine, University of Sao Paulo, Sao Paulo, Brazil, Tel: +55 (17) 32345858, Fax: +55 (17) 32140896; E-mail: rubenssiqueira@terra.com.br","PeriodicalId":318869,"journal":{"name":"Journal of Stem Cell Research and Medicine","volume":"89 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133116260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}